Seasoned corporate executive and investor with a background in operations, corporate finance and strategic M&A across healthcare and consumer sectors. Donna M Ryberg has led cross-functional teams, executed growth initiatives and served on boards, bringing private-equity and corporate-sponsor perspectives to capital allocation and portfolio oversight. Known for integrating commercial strategy with performance improvement, she is an active advisor to CEOs on buy-and-build plans, turnaround programs and exit readiness, with experience spanning public company reporting and stakeholder engagement.
Seasoned corporate executive and investor with a background in operations, corporate finance and strategic M&A across healthcare and consumer sectors. Donna M Ryberg has led cross-functional teams, executed growth initiatives and served on boards, bringing private-equity and corporate-sponsor perspectives to capital allocation and portfolio oversight. Known for integrating commercial strategy with performance improvement, she is an active advisor to CEOs on buy-and-build plans, turnaround programs and exit readiness, with experience spanning public company reporting and stakeholder engagement.
Combines operational rigor and corporate‑finance discipline to favor value creation through active ownership, performance improvement and strategic M&A. Prioritizes businesses in healthcare and consumer sectors where commercial strategy, margin enhancement and integration playbooks can accelerate growth; targets platforms suitable for buy‑and‑build rollups or turnaround interventions. Allocates capital with a bias toward control or significant influence, using tight governance, KPI‑driven oversight and staged capital deployment to de‑risk execution. Time horizon is medium to long‑term, focused on exit readiness and stakeholder alignment. Risk management emphasizes operational levers, cash‑flow resilience and measurable milestone‑based decision points.
Combines operational rigor and corporate‑finance discipline to favor value creation through active ownership, performance improvement and strategic M&A. Prioritizes businesses in healthcare and consumer sectors where commercial strategy, margin enhancement and integration playbooks can accelerate growth; targets platforms suitable for buy‑and‑build rollups or turnaround interventions. Allocates capital with a bias toward control or significant influence, using tight governance, KPI‑driven oversight and staged capital deployment to de‑risk execution. Time horizon is medium to long‑term, focused on exit readiness and stakeholder alignment. Risk management emphasizes operational levers, cash‑flow resilience and measurable milestone‑based decision points.
| Trades 895 | Longs Won 611/895 68% | Profit Factor 15.34 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $205,475.6 |
| Average Win $85,203 | Best Trade (Aug 05) $2.59M | Sharpe Ratio -12.23 |
| Average Loss -$11,951.93 | Worst Trade (Jun 29) -$156,215 | Z-Score 7.7 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 1w 1d | Expectancy $54,373.95 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 19,231 | 17,308 | 15,385 | 13,462 | 11,538 | 9,615 | 7,692 | 5,769 | 3,846 | 1,923 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 16,288 | $3.66M | $5.03M | - | $1.37M | 37.33% | -7.354% |
ABBV AbbVie Inc. | 852 | $211,406 | $213,800.88 | - | $2,394.88 | 1.13% | -2.513% |
ABT Abbott Laboratories | 4,016 | $420,382.02 | $424,491.2 | - | $4,109.18 | 0.98% | +0.085% |
AGG iShares Core U.S. Aggregate Bond ETF | 9,822 | $960,746.11 | $956,368.14 | - | -$4,377.97 | -0.46% | -0.256% |
AIRR First Trust RBA American Industrial Renaissance ETF | 24,631 | $1.93M | $2.88M | - | $953,448.91 | 49.41% | +1.588% |
AMAT Applied Materials, Inc. | 1,241 | $289,779.43 | $630,018.48 | - | $340,239.05 | 117.41% | +1.176% |
AMGN Amgen Inc. | 1,080 | $315,900.57 | $415,972.8 | - | $100,072.23 | 31.68% | -0.64% |
AMZN Amazon.com Inc | 8,093 | $1.64M | $2.2M | - | $555,273.17 | 33.8% | +15.321% |
ASML ASML Holding N.V. New York Registry Shares | 263 | $210,765.28 | $428,427 | - | $217,661.72 | 103.27% | -1.359% |
AVGO Broadcom Inc. | 2,519 | $719,164.34 | $980,596.32 | - | $261,431.98 | 36.35% | +0.371% |
BA Boeing Company | 1,004 | $216,372 | $217,004.56 | - | $632.56 | 0.29% | -2.155% |
BAC Bank of America Corporation | 27,801 | $1.11M | $1.72M | - | $615,678.12 | 55.64% | +0.356% |
BHP BHP Group Ltd. | 2,730 | $198,580.2 | $230,657.7 | - | $32,077.5 | 16.15% | -1.641% |
BRCC BRC Inc. | 1,938.8 | $60,476.01 | $19,969.64 | - | -$40,506.37 | -66.98% | +0.98% |
BRK-B Berkshire Hathaway Inc. | 3,168 | $1.31M | $1.62M | - | $312,643.51 | 23.9% | +0.365% |
BSV Vanguard Short-Term Bond ETF | 2,728 | $214,482.12 | $211,638.24 | - | -$2,843.88 | -1.33% | -0.077% |
C Citigroup Inc. | 3,920 | $251,585.37 | $519,204 | - | $267,618.63 | 106.37% | +0.098% |
CAT Caterpillar Inc. | 1,080 | $537,905.86 | $879,994.8 | - | $342,088.94 | 63.6% | +0.701% |
CDC VictoryShares US Equity Income Enhanced Volatility Wtd ETF | 8,186 | $479,374.63 | $623,175.62 | - | $143,800.99 | 30% | -0.369% |
CDL VictoryShares US Large Cap High Dividend ETF | 14,344 | $875,740.23 | $1.14M | - | $262,025.85 | 29.92% | -0.507% |